Covalon Technologies Ltd. Named as a TSX Venture Exchange 2025 Top 50 Company

Rhea-AI Summary

Covalon Technologies (TSXV: COV; OTCQX: CVALF) has been named to the TSX Venture Exchange 2025 Top 50 Company list, recognizing it among the top fifty performing companies on the TSXV over the past year. This prestigious acknowledgment highlights the company's significant market performance and growth in the advanced medical technologies sector.

CEO Brent Ashton expressed pride in this achievement, attributing it to the team's efforts in 2024 to create and capture value through differentiated product portfolios. He emphasized that the company is in the early stages of its value creation journey and maintains optimistic views about its long-term growth potential. Covalon remains focused on expanding its investor base while strengthening relationships with existing investors across the United States, Canada, and other markets.

MISSISSAUGA, Ontario--(BUSINESS WIRE)-- Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, is pleased to announce that it has been recognized by the TSX Venture Exchange (TSXV) as a 2025 Top 50 Company, an influential accomplishment honoring the top fifty performing companies on the TSXV over the past year.

“Being included on this prestigious list of TSXV-listed companies is an honor for Covalon,” said Brent Ashton, CEO of Covalon Technologies. “It’s a testament to the hard work of our entire team in 2024 to create and capture value through our differentiated product portfolios. We are still early in the value creation journey and are very excited for the long-term growth potential for the Company. As we expand our investor base, we remain committed to strengthening relationships with our existing investors in the United States, Canada and beyond.”

For more details on the 2025 TSXV Top 50, please visit www.tsx.com/venture50.

To learn more about Covalon, please visit our website at www.covalon.com or contact us at investors@covalon.com.

About Covalon

Covalon is a leading MedTech company dedicated to improving patient outcomes through innovative and compassionate medical products and technologies. Our expertise spans advanced wound care, vascular access, and surgical consumables, with a strong focus on enhancing healing, reducing healthcare-associated infections (HAIs), and protecting skin integrity. Our solutions are designed for patients and made for care providers. The Company is listed on the TSX Venture Exchange (COV) and trades on the OTCQX Market (CVALF). To learn more about Covalon, visit our website at www.covalon.com.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release may contain forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements are often, but not always, identified by the use of words such as "seek", "anticipate", "plan”, "estimate", "expect", "intend", or variations of such words and phrases or state that certain actions, events, or results “may”, “could”, “would”, “might”, “will” or “will be taken”, “occur”, or “be achieved”. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts, but instead represent management’s expectations, estimates, and projections regarding future events. Forward-looking statements involve risks and uncertainties, including, but not limited to, the factors described in greater detail in the “Risks and Uncertainties” section of our management’s discussion and analysis of financial condition and results of operations for the year ended September 30, 2024, which is available on the Company’s profile at www.sedarplus.ca, any of which could cause results, performance, or achievements to differ materially from the results discussed or implied in the forward-looking statements. Investors should not place undue reliance on any forward-looking statements. The forward-looking statements contained in this news release are made as of the date of this news release, and the Company assumes no obligation to update or alter any forward-looking statements, whether as a result of new information, further events, or otherwise, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250219273028/en/

To learn more about Covalon, please contact:

Investor Relations, Covalon Technologies Ltd.

Email: investors@covalon.com

Website: https://covalon.com/

Source: Covalon Technologies Ltd.

FAQ

What recognition did Covalon Technologies (CVALF) receive from TSX Venture Exchange in 2025?

Covalon Technologies was named as one of the TSX Venture Exchange 2025 Top 50 Companies, recognizing it among the top fifty performing companies on the TSXV over the past year.

How did Covalon Technologies (CVALF) perform in 2024 to earn the TSXV Top 50 recognition?

According to CEO Brent Ashton, the company created and captured value through differentiated product portfolios, demonstrating strong performance that led to its inclusion in the TSXV Top 50 list.

What are Covalon Technologies' (CVALF) growth plans following the TSXV Top 50 recognition?

Covalon plans to expand its investor base while strengthening relationships with existing investors in the United States, Canada, and beyond, viewing itself as early in its value creation journey with significant long-term growth potential.

What stock exchanges is Covalon Technologies listed on in 2025?

Covalon Technologies is listed on the TSX Venture Exchange (TSXV: COV) and the OTCQX market (OTCQX: CVALF).